| abstract |
The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol ring and a 6,7-dihydro-5H- pyrrolo[l,2-c]imidazole ring system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/ C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer. (formula) |